First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
- DOI
- 10.1016/j.jtocrr.2025.100868
- Published
- 2025-10
- Container
- JTO Clinical and Research Reports
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2025.100868,
title = {First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis},
author = {Koichi Goto and Herbert H. Loong and Caicun Zhou and Kazumi Nishino and Dae Ho Lee and Se-Hoon Lee and James Chih-Hsin Yang and Dan Liu and Minji Kim Uh and Hongmei Han and Tarun Puri and Aimee Bence Lin and Ying Cheng},
year = {2025},
journal = {JTO Clinical and Research Reports},
doi = {10.1016/j.jtocrr.2025.100868},
url = {https://doi.org/10.1016/j.jtocrr.2025.100868}
}RIS
TY - JOUR TI - First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis AU - Koichi Goto AU - Herbert H. Loong AU - Caicun Zhou AU - Kazumi Nishino AU - Dae Ho Lee AU - Se-Hoon Lee AU - James Chih-Hsin Yang AU - Dan Liu AU - Minji Kim Uh AU - Hongmei Han AU - Tarun Puri AU - Aimee Bence Lin AU - Ying Cheng PY - 2025 JO - JTO Clinical and Research Reports DO - 10.1016/j.jtocrr.2025.100868 UR - https://doi.org/10.1016/j.jtocrr.2025.100868 ER -
APA
Goto, K., Loong, H. H., Zhou, C., Nishino, K., Lee, D. H., Lee, S., Yang, J. C., Liu, D., Uh, M. K., Han, H., Puri, T., Lin, A. B., & Cheng, Y. (2025). First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2025.100868
Source records
- crossref · retrieved 2026-09-27T10:46:28.248Z